Full Text View
Tabular View
No Study Results Posted
Related Studies
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
This study is ongoing, but not recruiting participants.
Study NCT00402766   Information provided by M.D. Anderson Cancer Center

First Received on November 20, 2006.   Last Updated on March 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mesothelioma
More general conditions related to this trial
Adenoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Interventions listed in this trial
Cisplatin
Imatinib Mesylate
Pemetrexed
Additional drug interventions recognized in this trial
Folic Acid Antagonists
Imatinib
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services